Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
UK Pharmaceuticals And Healthcare Industry
SWOT — 6
United Kingdom Political
SWOT — 7
United Kingdom Economic
SWOT — 7
Pharmaceutical Business Environment
Ratings — 8
Table: Western Europe Pharmaceuticals Business
Environment Ratings For Q209 — 8
Limits of Potential
Returns — 8
Risks to Realisation of
Returns — 9
UK – Market
Summary — 10
Regulatory Regime — 12
Recent NICE Recommendations — 14
Innovative
Medicines — 16
Generic Medicines — 17
OTC Medicines — 18
Recent EU Regulatory
Developments — 19
Intellectual Property
Issues — 21
Counterfeit
Pharmaceuticals — 22
Table: Examples Of Recalls Of
Counterfeit Medicines In The UK — 23
Pricing
Regime — 25
Reimbursement Regime — 28
Industry Developments — 29
Epidemiology — 29
Healthcare
Sector — 30
Healthcare Financing — 31
Health Insurance — 33
Wholesale
Sector — 34
Retail Sector — 36
Table:
Registered Pharmacy Premises In The UK (2007) — 37
Parallel Imports — 38
Health
Tourism — 40
Research and Development
Sector — 41
Clinical Trials — 42
Biotechnology — 45
Medical
Devices — 46
Industry Forecast
Scenario — 48
Overall Market
Forecast — 48
Table: UK’s Drug Market Indicators,
2004-2013 — 49
Key Growth Factors –
Industry — 50
Table: UK’s Health Expenditure
Indicators, 2004-2013 — 51
Key Growth Factors –
Macroeconomic — 52
Table: United Kingdom –
Macroeconomic Forecasts, 2004-2013 — 53
Prescription Drug
Market Forecast — 54
Table: UK’s Prescription Drug
Market Indicators, 2004-2013 (GBPmn unless otherwise
indicated) — 55
OTC Market
Forecast — 56
Table: UK’s OTC Market Indicators,
2004-2013 (GBPmn unless otherwise stated) — 58
Patented
Market Forecast — 59
Table: UK’s Patented Market
Indicators Forecast, 2004-2013 — 60
Generics Market
Forecasts — 61
Table: UK’s Generics Market
Indicators, 2004-2013 — 62
Export/Import
Forecasts — 63
Table: UK’s Sectoral Trade Forecast
Indicators, 2004-2013 (US$mn) — 64
Key Risks to BMI
Forecasts — 64
Competitive
Landscape — 65
Table: Leading Pharmaceutical Corporations
in the UK by Market Share (2007) — 66
Table: Top
pharmaceutical products in the UK (2007) — 67
Table: Cost
Of Prescriptions* Dispensed In Various Disease Areas
(GBPmn) — 69
Company Profiles — 70
Leading Multinational Manufacturers — 70
Pfizer — 70
Novartis — 73
Sanofi-Aventis — 75
Merck & Co — 77
Leading Indigenous Manufacturers — 79
GlaxoSmithKline — 79
AstraZeneca — 85
Country Snapshot: UK Demographic Data — 89
Section 1:
Population — 89
Table: Demographic Indicators,
2005-2030 — 89
Table: Rural/Urban Breakdown,
2005-2030 — 90
Section 2: Education and
Healthcare — 90
Table: Education,
2002-2005 — 90
Table: Vital Statistics,
2005-2030 — 90
Section 3: Labour Market and Spending
Power — 91
Table: Employment Indicators,
2000-2005 — 91
Table: Consumer Expenditure, 2000-2011
(US$) — 91
Table: Average Annual Wages,
2000-2012 — 92
BMI Forecast
Modelling — 93
How We Generate Our Pharmaceutical Industry
Forecasts — 93
Pharmaceutical Business Environment Ratings
Methodology — 94
Ratings Overview — 94
Table: Pharmaceutical Business Environment Indicators — 95
Weighting — 96
Table: Weighting Of
Components — 96
Sources — 96
| 
View Cart
